Our objective is to present the pharmacological mechanisms, safety profiles, and regulatory status of prominent approved and unapproved peptides marketed direct to patients, including AOD-9604 (anti-obesity drug 9604), BPC-157 (body protection compound 157), CJC-1295, FS-344 (follistatin-344), GHK-Cu (glycyl-l-histidyl-l-lysine copper), ipamorelin, MOTS-C (mitochondrial ORF of the 12S rRNA type-c), sermorelin, SS-31 (elamipretide), tesamorelin (Egrifta), T4 (thymosin beta-4), and TB-500 (thymosin beta-4 fragment)
Suggested Use Gently shake before opening
doi: 10.2174/1871527317666180625101643 91
Kissela B, Broderick J, Woo D, Kothari R, Miller R, Khoury J, et al: Greater Cincinnati/Northern Kentucky Stroke Study: volume of first-ever ischemic stroke among blacks in a population-based study
In fact, it burns nearly 3x more than fat at rest
Researchers at Virginia Tech's Fralin Biomedical Research Institute analyzed how 20 adults with obesity half of whom had been taking GLP-1 receptor agonists for at least four weeks reacted to alcoholic drinks compared to participants not on the drugs
